Premium
Molecular modelling of the androgen receptor axis: rational basis for androgen receptor intervention in androgen‐independent prostate cancer
Author(s) -
FLETTERICK ROBERT J.
Publication year - 2005
Publication title -
bju international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 1464-4096
DOI - 10.1111/j.1464-410x.2005.05940.x
Subject(s) - androgen receptor , prostate cancer , androgen , nuclear receptor , cancer research , chemistry , receptor , medicine , endocrinology , computational biology , biology , cancer , transcription factor , biochemistry , hormone , gene
Androgen depletion in combination with antiandrogenic agents is initially highly effective for treating prostate cancer, and is the recommended treatment for more advanced or higher‐grade tumours. However, many tumours eventually become insensitive to androgens, even though the androgen receptor (AR) continues to be expressed. Computational chemistry combined with structural analysis of nuclear receptors and determination of binding affinities of natural and designed coregulators (coactivators and corepressors) provides the theoretical framework for the rational design of novel therapeutic agents directed at the AR. Adding alternative groups to various sites throughout the receptor can alter the conformation of the molecule and its functional binding with coactivators or corepressors. Possible molecules can be identified thoroughly and systematically using intelligent high‐throughput screening and FASTrack chemistry (three‐dimensional crystallography). Applying these techniques should eventually result in therapeutic agents for androgen‐independent prostate cancer that can block binding of AR coactivators while simultaneously increasing binding of AR corepressors.